Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MYO vs TENX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TENX Captures Overall Composite Edge (45.5 HOLD vs 40.1 SELL), While MYO Leads 3–2 on Growth & Valuation Pillars

TENX Overall Winner 6-Pillar Tally: MYO 3 – 2 TENX (1 Tie) Matrix Metrics: MYO 2 – 8 TENX

As of Nov 20, 2026, Tenax Therapeutics, Inc. (TENX) captures the overall head-to-head institutional edge over Myomo Inc. (MYO) on higher Unified Composite conviction (45.5/100 HOLD vs. 40.1/100 SELL) after splitting the core matrix 8–2 (led by Valuation Multiples, Profitability & Quality), while MYO wins 3–2 across the 6-pillar growth and valuation breakdown. MYO trades at $0.81 (N/M Forward P/E, -21.8% operating margin) versus TENX at $1.25 (0.3x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: TENX earns the overall head-to-head edge with a stronger Unified Composite Score (45.5/100 HOLD vs. MYO 40.1/100 SELL) and 1.42β · 75% Vol risk profile, whereas MYO leads top-line expansion (+22.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile TENX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MYO vs TENX
MYO NYSE American
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32
TENX NASDAQ Head-to-Head Winner
Tenax Therapeutics, Inc.
Pharmaceutical Preparations
$1.25
-10.07% 1D
Market Cap $63.3M
TTM Revenue N/A
Forward P/E 0.3x
Beta / 30D Vol 1.42β · 75% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 57.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.8%), weak momentum, RSI 30
RSI-14: 29.5 · SMA20: $1.65 · SMA50: $1.74

6-Pillar Scorecard Institutional Category Breakdown (MYO 3 – 2 TENX)

Columns: Metric · MYO · TENX
1. Valuation Multiples TENX
Forward P/E N/M 0.3x
Trailing P/E N/M 0.3x
PEG Ratio N/M 1.44x
EV / Revenue 0.9x N/M
2. Growth & Scale MYO
Revenue Growth (YoY) +22.2% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $46M N/A
Market Cap $33.7M $63.3M
3. Profitability & Quality TENX
Gross Margin 70.1% N/A
Operating Margin -21.8% 0.0%
Net Profit Margin -33.1% 0.0%
Return on Equity (ROE) -173.5% -64.2%
4. Balance Sheet & Cash Flow MYO
Cash Generation (TTM) -$9.1M -$49M
Cash Flow Margin -20.0% N/A
Net Cash / Leverage $8.9M Net Debt (3.44x D/E) $2.03 Book/Sh · -64.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 266.0% (81st %ile) 148.9% (24th %ile)
Put/Call OI Skew N/A 0.08x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MYO (2) vs TENX (8)
Institutional Metric MYO TENX Criterion Row Edge
Market Capitalization
Scale
$33.7M $63.3M Larger Scale TENX
Trailing P/E Ratio
Valuation
N/M 0.3x Lower Multiple TENX
Forward P/E Ratio
Valuation
N/M 0.3x Lower Multiple TENX
Revenue Growth (YoY)
Growth
+22.2% +0.0% Higher Growth MYO
Operating Margin (TTM)
Profitability
-21.8% 0.0% Higher Margin TENX
Net Profit Margin
Profitability
-33.1% 0.0% Higher Margin TENX
Return on Equity (ROE)
Capital Efficiency
-173.5% -64.2% Higher ROE TENX
52-Week Range Position
Momentum
16% ($1–$2) 0% ($1–$19) Stronger Trend MYO
Beta / 30D Volatility
Risk Regime
2.22β · 107% Vol 1.42β · 75% Vol Lower Realized Risk TENX
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 45.5 / 100 (HOLD) Higher Composite TENX
Trailing 12M Revenue (USD)
Operating Scale
$46M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev 1.44x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.1M ($8.9M Net Debt (3.44x D/E)) -$49M ($2.03 Book/Sh · -64.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TENX +4.54 pp
MYO: -33.52% · TENX: -28.98%
3M Horizon TENX +9.22 pp
MYO: -41.65% · TENX: -32.43%
6M Horizon MYO +67.67 pp
MYO: -22.02% · TENX: -89.69%
1Y Horizon MYO +95.22 pp
MYO: +12.3% · TENX: -82.92%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MYO Revenue TENX Revenue MYO Op. Margin TENX Op. Margin Margin Leader
FY2018 $0M N/A -430.8% N/A MYO
FY2019 $0M N/A -281.3% N/A MYO
FY2020 $10M N/A -138.5% N/A MYO
FY2021 $10M N/A -74.1% N/A MYO
FY2022 $20M N/A -68.6% N/A MYO
FY2023 $20M N/A -42.8% N/A MYO
FY2024 $30M N/A -19.1% N/A MYO
FY2025 $40M N/A -35.2% N/A MYO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TENX BREAKDOWN
95d in phase · OBV DISTRIBUTION
Current IV 148.9%
IV Percentile 24th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TENX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TENX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $63.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MYO vs TENX Key Questions & Quantitative Answers

As of Nov 20, 2026, Tenax Therapeutics, Inc. (TENX) captures the overall head-to-head institutional edge over Myomo Inc. (MYO) on higher Unified Composite conviction (45.5/100 HOLD vs. 40.1/100 SELL) after splitting the core matrix 8–2 (led by Valuation Multiples, Profitability & Quality), while MYO wins 3–2 across the 6-pillar growth and valuation breakdown. MYO trades at $0.81 (N/M Forward P/E, -21.8% operating margin) versus TENX at $1.25 (0.3x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: TENX earns the overall head-to-head edge with a stronger Unified Composite Score (45.5/100 HOLD vs. MYO 40.1/100 SELL) and 1.42β · 75% Vol risk profile, whereas MYO leads top-line expansion (+22.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile TENX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MYO leads the Growth & Scale pillar: MYO posts +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin), compared with TENX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MYO cumulative revenue shifted +300.0% while TENX shifted N/A. In operating R&D and SG&A reinvestment, MYO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TENX.

TENX screens cheaper on headline valuation multiples. MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin), whereas TENX trades at 0.3x Forward P/E, 0.3x Trailing P/E, 1.44x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYO (-173.5% ROE) versus TENX (-64.2% ROE) capital efficiency.

In options market volatility and institutional positioning, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk). By comparison, TENX carries 148.9% implied volatility (24th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.